A new drug appeared to slash seizures up to 90% in children with a rare and devastating form of epilepsy called Dravet syndrome by tackling the underlying genetic mutation that causes the condition.
The findings are in an early-stage trial not designed to show efficacy, so it's not yet clear whether the results will hold up in a larger trial. But if they do, it would be the first drug with the potential to alter the trajectory of the disease, which comes with neurodevelopmental delays and a high risk of sudden death.
